Key Highlights
● Vir's Phase 3 hepatitis Delta trial met its primary endpoint.
● Edesa licensed paridiprubart to Kyorin for $12 million upfront.
● Faeth, Janux, ImmunityBio and NovoCure fell on misses.
● Eli Lilly rose after a Canadian reimbursement recommendation.
Biotech investors got a sharp reminder on Monday, November 9, 2026, that the sector runs on data. While the broader market rallied, with the S&P 500 jumping 173.08 points to 7,549.94, individual drug stocks lived or died by trial readouts and Earnings guidance.
The winners
Vir Biotechnology (NASDAQ:VIR) climbed sharply after its Phase 3 ECLIPSE 1 trial in chronic hepatitis delta met its primary endpoint, according to news reports. The company plans to file with the FDA in mid-2027.
Immunovant (NASDAQ:IMVT) also jumped after the higher dose of its FcRn inhibitor IMVT-1402 met the main goal of a rheumatoid arthritis trial. According to market coverage, about nine in ten patients on the drug hit the ACR20 response measure at Week 28, compared with roughly three in four on placebo.
Edesa Biotech (NASDAQ:EDSA) rose after licensing paridiprubart to Kyorin for Japan, a deal worth $12 million upfront and up to about $134 million in milestones.
After the close, Definium Therapeutics (NASDAQ:DFTX), formerly MindMed, highlighted two positive Phase 3 studies of its DT120 treatment in generalized anxiety disorder. The shares had already closed higher at $35.39. CEO Rob Barrow said on the earnings call, "we have moved beyond demonstrating the promise of DT120 ODT".
The painful misses
On the other side, Zura Bio (NASDAQ:ZURA) plunged after its tibulizumab failed its primary goal in a 247-patient Phase 2 study in hidradenitis suppurativa, according to market reports. It was the biggest small-cap decliner.
Faeth Therapeutics (NASDAQ:FTH) tumbled after early Phase 2 results in advanced endometrial cancer showed tumor shrinkage in about a third of assessable patients, which was described as below investor hopes after a run-up into the data. Janux Therapeutics (NASDAQ:JANX) sank after first data for JANX011 in 25 healthy volunteers disappointed investors.
Commercial updates hurt too. Ionis Pharmaceuticals (NASDAQ:IONS) plunged after cutting its 2026 sales forecast for Tryngolza to about $50 million from $100 million to $110 million, citing a slower launch, even as total Revenue jumped, according to market data. ImmunityBio (NASDAQ:IBRX) sank despite strong growth in Anktiva sales, and NovoCure (NASDAQ:NVCR) fell after receiving an FDA Not Approvable Letter for its Optune Mya application.
Deals keep coming
Dealmaking added a steadier thread. Argenx agreed to buy Unnatural Products for up to $1.15 billion, and Charles River Laboratories (NYSE:CRL) agreed to acquire Frontage's bioanalysis and DMPK operations for roughly $470 million in cash, according to news reports. In big pharma, Eli Lilly (NYSE:LLY) rose after Canada's drug agency recommended reimbursement for its Alzheimer's drug Kisunla, according to market coverage, while the FDA required Lilly and Novo Nordisk to warn of a rare possible vision side effect on GLP-1 drugs.
Broader market strength offered little cover for the losers. The small-cap Russell 2000, home to many young drug developers, surged 86.71 points to 2,840.81, yet the worst biotech decliners still tumbled, showing how company-specific data can overwhelm any market tide.
Data Decides Winners and Losers
The split day underlines that biotech moves on catalysts, not market mood. Vir's FDA filing timeline, Immunovant's next steps for IMVT-1402 and Definium's planned 2027 drug application are milestones to track. Ionis investors will watch for signs the Tryngolza launch can pick up. More broadly, higher interest rates tend to weigh on cash-burning biotechs, so Tuesday's October Inflation report and the Fed's December meeting matter for the whole group.






Please wait processing your request...